Trial Outcomes & Findings for Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (NCT NCT03706079)

Last Updated: 2023-06-06

Results Overview

Includes adverse events with an onset date between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set. Exposure adjusted rates are defined as number of subjects with AEs divided by total time at risk across all subjects, multiplied by 100

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

951 participants

Primary outcome timeframe

Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.

Results posted on

2023-06-06

Participant Flow

Participants who completed treatment and attended end of treatment visit in predecessor studies NAVIGATOR (NCT03347279) or SOURCE (NCT03406078) were eligible for this long-term extension study. In the predecessor studies, a total of 1059 and 150 subjects were randomised and dosed in NAVIGATOR and SOURCE respectively. In DESTINATION, a total of 951 subjects (827 from NAVIGATOR and 124 from SOURCE) were randomised at 182 centres in 18 countries to receive treatment with tezepelumab or placebo.

Of the 1209 patients randomized and dosed in predecessor studies, 951 were randomised in DESTINATION and 950 received treatment. The patients receiving tezepelumab in the predecessors continued to receive tezepelumab, while patients receiving placebo in the predecessors were re-randomized 1:1 to either receive tezepelumab in DESTINATION or to continue placebo, resulting in a 3:1 randomization ratio in DESTINATION.

Participant milestones

Participant milestones
Measure	NAVIGATOR Rand Teze All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the NAVIGATOR Pbo to Teze arm.	NAVIGATOR Pbo to Teze All subjects randomised to placebo in the NAVIGATOR predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.	SOURCE Rand Teze All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the SOURCE Pbo to Teze arm.	SOURCE Pbo to Teze All subjects randomised to placebo in the SOURCE predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.
Predecessor Study STARTED	529	532	0	74	76	0
Predecessor Study Received Treatment	528	531	0	74	76	0
Predecessor Study COMPLETED	513	509	0	68	73	0
Predecessor Study NOT COMPLETED	16	23	0	6	3	0
Long Term Extension (DESTINATION) STARTED	415	206	206	60	32	32
Long Term Extension (DESTINATION) Received Treatment	415	206	205	60	32	32
Long Term Extension (DESTINATION) COMPLETED	400	200	198	58	28	31
Long Term Extension (DESTINATION) NOT COMPLETED	15	6	8	2	4	1

Reasons for withdrawal

Reasons for withdrawal
Measure	NAVIGATOR Rand Teze All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the NAVIGATOR Pbo to Teze arm.	NAVIGATOR Pbo to Teze All subjects randomised to placebo in the NAVIGATOR predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.	SOURCE Rand Teze All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the SOURCE Pbo to Teze arm.	SOURCE Pbo to Teze All subjects randomised to placebo in the SOURCE predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.
Predecessor Study Death	0	2	0	1	0	0
Predecessor Study Lost to Follow-up	5	2	0	0	1	0
Predecessor Study Withdrawal by Subject	8	15	0	5	2	0
Predecessor Study Did not receive treatment / Non-compliance with protocol / did not complete safety follow-up visits	3	4	0	0	0	0
Long Term Extension (DESTINATION) Due to COVID-19 pandemic	0	0	0	0	0	1
Long Term Extension (DESTINATION) Did not complete safety follow-up visits	1	0	2	0	0	0
Long Term Extension (DESTINATION) Pregnancy	1	0	0	0	0	0
Long Term Extension (DESTINATION) Withdrawal by Subject	3	3	3	1	3	0
Long Term Extension (DESTINATION) Lost to Follow-up	2	1	1	0	1	0
Long Term Extension (DESTINATION) Death	8	2	2	1	0	0

Baseline Characteristics

Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	NAVIGATOR Rand Teze n=528 Participants All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo n=531 Participants All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study and regardless of their treatment assignment in DESTINATION.	SOURCE Rand Teze n=74 Participants All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo n=76 Participants All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study and regardless of their treatment assignment in DESTINATION.	Total n=1209 Participants Total of all reporting groups
Age, Categorical <=18 years	41 Participants n=5 Participants	41 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	82 Participants n=21 Participants
Age, Categorical Between 18 and 65 years	391 Participants n=5 Participants	416 Participants n=7 Participants	58 Participants n=5 Participants	62 Participants n=4 Participants	927 Participants n=21 Participants
Age, Categorical >=65 years	96 Participants n=5 Participants	74 Participants n=7 Participants	16 Participants n=5 Participants	14 Participants n=4 Participants	200 Participants n=21 Participants
Age, Continuous	49.9 Years STANDARD_DEVIATION 16.3 • n=5 Participants	49.0 Years STANDARD_DEVIATION 15.9 • n=7 Participants	53.5 Years STANDARD_DEVIATION 12.1 • n=5 Participants	53.4 Years STANDARD_DEVIATION 11.9 • n=4 Participants	49.9 Years STANDARD_DEVIATION 15.7 • n=21 Participants
Sex: Female, Male Female	335 Participants n=5 Participants	337 Participants n=7 Participants	49 Participants n=5 Participants	45 Participants n=4 Participants	766 Participants n=21 Participants
Sex: Female, Male Male	193 Participants n=5 Participants	194 Participants n=7 Participants	25 Participants n=5 Participants	31 Participants n=4 Participants	443 Participants n=21 Participants
Race/Ethnicity, Customized Hispanic or Latino	83 Participants n=5 Participants	81 Participants n=7 Participants	10 Participants n=5 Participants	14 Participants n=4 Participants	188 Participants n=21 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	445 Participants n=5 Participants	450 Participants n=7 Participants	64 Participants n=5 Participants	62 Participants n=4 Participants	1021 Participants n=21 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized Asian	146 Participants n=5 Participants	149 Participants n=7 Participants	11 Participants n=5 Participants	11 Participants n=4 Participants	317 Participants n=21 Participants
Race/Ethnicity, Customized Black of African American	30 Participants n=5 Participants	31 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	62 Participants n=21 Participants
Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants
Race/Ethnicity, Customized Other	19 Participants n=5 Participants	23 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	43 Participants n=21 Participants
Race/Ethnicity, Customized White	332 Participants n=5 Participants	327 Participants n=7 Participants	62 Participants n=5 Participants	64 Participants n=4 Participants	785 Participants n=21 Participants

PRIMARY outcome

Timeframe: Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.

Outcome measures

Outcome measures
Measure	NAVIGATOR Rand Teze n=528 Participants All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo n=531 Participants All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.	SOURCE Rand Teze n=74 Participants All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo n=76 Participants All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Exposure Adjusted Incidence Rates of AEs/SAEs Any AE incidence rate	49.62 Patients with AEs per 100 person-years	62.66 Patients with AEs per 100 person-years	47.15 Patients with AEs per 100 person-years	69.97 Patients with AEs per 100 person-years
Exposure Adjusted Incidence Rates of AEs/SAEs Any AE with outcome=death incidence rate	0.76 Patients with AEs per 100 person-years	0.14 Patients with AEs per 100 person-years	1.55 Patients with AEs per 100 person-years	0.00 Patients with AEs per 100 person-years
Exposure Adjusted Incidence Rates of AEs/SAEs Any SAE incidence rate	7.85 Patients with AEs per 100 person-years	12.45 Patients with AEs per 100 person-years	13.14 Patients with AEs per 100 person-years	17.99 Patients with AEs per 100 person-years
Exposure Adjusted Incidence Rates of AEs/SAEs Any AE leading to discontinuation of IP incidence rate	1.64 Patients with AEs per 100 person-years	3.00 Patients with AEs per 100 person-years	1.55 Patients with AEs per 100 person-years	2.00 Patients with AEs per 100 person-years

PRIMARY outcome

Includes time between the date of first dose of IP in the predecessor and minimum (date of last dose of IP + 33 days, date of death, date of study withdrawal, day prior to start of another biologic). The analysis is based on the Safety Analysis Set.

Outcome measures

Outcome measures
Measure	NAVIGATOR Rand Teze n=528 Participants All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo n=531 Participants All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.	SOURCE Rand Teze n=74 Participants All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo n=76 Participants All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Total Time at Risk	917.0 Year	699.0 Year	129.4 Year	100.0 Year

SECONDARY outcome

The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF. The analysis is based on the primary population (Full Analysis Set)

Outcome measures

Outcome measures
Measure	NAVIGATOR Rand Teze n=528 Participants All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo n=531 Participants All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.	SOURCE Rand Teze n=74 Participants All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo n=76 Participants All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.
Annualized Asthma Exacerbation Rate (AAER)	0.82 events per year Interval 0.71 to 0.95	1.93 events per year Interval 1.7 to 2.2	1.07 events per year Interval 0.76 to 1.51	1.76 events per year Interval 1.27 to 2.45

Adverse Events

NAVIGATOR Rand Teze

Serious events: 82 serious events

Other events: 390 other events

Deaths: 8 deaths

NAVIGATOR Rand Pbo

Serious events: 94 serious events

Other events: 384 other events

Deaths: 5 deaths

NAVIGATOR Pbo to Teze

Serious events: 17 serious events

Other events: 98 other events

Deaths: 1 deaths

SOURCE Rand Teze

Serious events: 18 serious events

Other events: 53 other events

Deaths: 2 deaths

SOURCE Rand Pbo

Serious events: 19 serious events

Other events: 58 other events

Deaths: 0 deaths

SOURCE Pbo to Teze

Serious events: 4 serious events

Other events: 23 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	NAVIGATOR Rand Teze n=528 participants at risk All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo n=531 participants at risk All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the NAVIGATOR Pbo to Teze arm.	NAVIGATOR Pbo to Teze n=206 participants at risk All subjects randomised to placebo in the NAVIGATOR predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.	SOURCE Rand Teze n=74 participants at risk All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo n=76 participants at risk All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the SOURCE Pbo to Teze arm.	SOURCE Pbo to Teze n=32 participants at risk All subjects randomised to placebo in the SOURCE predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.
Cardiac disorders Cardiac failure congestive	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Head injury	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Hip fracture	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Upper respiratory tract infection	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Coronary artery disease	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Ligament sprain	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Periprocedural myocardial infarction	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Radius fracture	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Road traffic accident	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Coronary artery occlusion	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Ulna fracture	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Ligament rupture	0.57% 3/528 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Myocardial infarction	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Tendon rupture	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Investigations Blood creatine phosphokinase increased	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Diabetes mellitus inadequate control	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Muscle necrosis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Myocarditis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Gout	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Myositis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Type 1 diabetes mellitus	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Amyotrophy	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Bone cyst	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Palpitations	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Exostosis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive breast carcinoma	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Umbilical hernia	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Polyarthritis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Prinzmetal angina	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Spinal stenosis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Spondylolisthesis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Supraventricular tachycardia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Ventricular extrasystoles	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Congenital, familial and genetic disorders Encephalocele	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Blood and lymphatic system disorders Immune thrombocytopenia	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Congenital, familial and genetic disorders Hypertrophic cardiomyopathy	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Ear and labyrinth disorders Vertigo positional	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Eye disorders Cataract	0.19% 1/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Anal fistula	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Eye disorders Uveitis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Diverticular perforation	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Acute left ventricular failure	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Gastric polyps	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Ileus paralytic	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Inguinal hernia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Large intestine polyp	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Rectal haemorrhage	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Acute myocardial infarction	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Oesophageal achalasia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Pancreatitis acute	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Pancreatitis necrotising	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Death	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.56% 3/531 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Impaired healing	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Aortic valve stenosis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Hepatobiliary disorders Cholecystitis chronic	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Non-cardiac chest pain	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Immune system disorders Anaphylactic reaction	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Immune system disorders Drug hypersensitivity	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Atrial flutter	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Breast abscess	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Bacterial pyelonephritis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Atrial tachycardia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Covid-19	0.57% 3/528 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Covid-19 pneumonia	0.57% 3/528 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Cellulitis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations H1n1 influenza	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Gastroenteritis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Gastroenteritis viral	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Cardiac arrest	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Intervertebral discitis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Lower respiratory tract infection bacterial	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Meningitis bacterial	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia bacterial	0.57% 3/528 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia haemophilus	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Cardiac disorders Cardiac failure	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Osteomyelitis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia streptococcal	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Periorbital cellulitis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia	0.19% 1/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia klebsiella	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Ovarian germ cell teratoma benign	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign neoplasm of thyroid gland	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon adenoma	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer stage iv	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma in situ	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neurilemmoma benign	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostatic adenoma	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of the oral cavity	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thymoma	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Renal and urinary disorders Acute kidney injury	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Renal and urinary disorders Glomerulonephritis membranous	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Cerebrovascular accident	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Renal and urinary disorders Renal colic	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Cubital tunnel syndrome	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Dizziness	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Haemorrhagic stroke	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Headache	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Asthma	3.0% 16/528 • Number of events 20 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	8.1% 43/531 • Number of events 91 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.8% 5/74 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	10.5% 8/76 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Idiopathic generalised epilepsy	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Intracranial aneurysm	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Lumbar radiculopathy	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Migraine	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Myelopathy	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Ruptured cerebral aneurysm	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Transient ischaemic attack	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Psychiatric disorders Disruptive mood dysregulation disorder	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Renal and urinary disorders Nephrolithiasis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Obstruction gastric	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Chest discomfort	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Malaise	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Atypical pneumonia	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Cholecystitis infective	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Herpes zoster oticus	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Diverticulitis	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Gastroenteritis salmonella	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia viral	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Sepsis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Septic shock	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Incisional hernia	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Seizure	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Pregnancy, puerperium and perinatal conditions Abortion spontaneous	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Psychiatric disorders Bipolar disorder	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Renal and urinary disorders Ureterolithiasis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Reproductive system and breast disorders Ovarian cyst	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Reproductive system and breast disorders Uterine prolapse	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Bronchial secretion retention	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Eosinophilic pneumonia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Haemothorax	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Nasal polyps	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Pulmonary sarcoidosis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Endocrine disorders Hyperparathyroidism primary	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Dermatitis contact	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Rash	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Vascular disorders Cyanosis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Vascular disorders Haematoma	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Vascular disorders Hypertension	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Vascular disorders Peripheral arterial occlusive disease	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Vascular disorders Thrombosis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Colitis	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Colitis ischaemic	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Gait disturbance	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Hepatobiliary disorders Cholelithiasis	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Anal abscess	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Appendicitis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Influenza	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Lower respiratory tract infection	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Lung abscess	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia aspiration	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia staphylococcal	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.

Other adverse events

Other adverse events
Measure	NAVIGATOR Rand Teze n=528 participants at risk All subjects randomised to tezepelumab in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	NAVIGATOR Rand Pbo n=531 participants at risk All subjects randomised to placebo in the NAVIGATOR predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the NAVIGATOR Pbo to Teze arm.	NAVIGATOR Pbo to Teze n=206 participants at risk All subjects randomised to placebo in the NAVIGATOR predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.	SOURCE Rand Teze n=74 participants at risk All subjects randomised to tezepelumab in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study.	SOURCE Rand Pbo n=76 participants at risk All subjects randomised to placebo in the SOURCE predecessor and treated with at least one dose in the predecessor, regardless of whether they participated in the DESTINATION study. For subjects switching to tezepelumab in DESTINATION, data collected during the placebo (predecessor) period are contained in this column, while data collected after the first dose of tezepelumab in DESTINATION are presented in the SOURCE Pbo to Teze arm.	SOURCE Pbo to Teze n=32 participants at risk All subjects randomised to placebo in the SOURCE predecessor and re-randomised to tezepelumab in DESTINATION. Only data collected after the first dose of tezepelumab in DESTINATION are presented in this column.
Infections and infestations Sinusitis	5.7% 30/528 • Number of events 34 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	8.1% 43/531 • Number of events 64 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.7% 2/74 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.6% 5/76 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Traumatic haematoma	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Rhinitis	3.4% 18/528 • Number of events 24 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.0% 21/531 • Number of events 42 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.9% 6/206 • Number of events 26 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	5.4% 4/74 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Sinusitis bacterial	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.8% 5/74 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Upper respiratory tract infection bacterial	1.5% 8/528 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Vaginal infection	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.56% 3/531 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Hyperlipidaemia	0.76% 4/528 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Type 2 diabetes mellitus	3.0% 16/528 • Number of events 16 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 8/531 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 3/206 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Back pain	6.8% 36/528 • Number of events 49 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.7% 25/531 • Number of events 30 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Vertebral foraminal stenosis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Hyposmia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Spinal cord disorder	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Psychiatric disorders Anxiety	2.1% 11/528 • Number of events 13 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 8/531 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Diarrhoea	2.8% 15/528 • Number of events 15 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 8/531 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.7% 2/74 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Gastrooesophageal reflux disease	1.7% 9/528 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 8/531 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Hepatobiliary disorders Cholelithiasis	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Acute sinusitis	3.0% 16/528 • Number of events 23 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.0% 16/531 • Number of events 26 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Bronchitis bacterial	5.7% 30/528 • Number of events 34 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.6% 19/531 • Number of events 24 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 3/206 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	10.8% 8/74 • Number of events 20 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	9.2% 7/76 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	9.4% 3/32 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Bronchitis viral	0.38% 2/528 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.2% 2/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Oral candidiasis	2.3% 12/528 • Number of events 16 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.8% 15/531 • Number of events 17 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.8% 5/74 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	7.9% 6/76 • Number of events 11 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.2% 2/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pharyngitis	4.9% 26/528 • Number of events 35 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.3% 23/531 • Number of events 28 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.6% 2/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Pneumonia haemophilus	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Suspected covid-19	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Tinea versicolour	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Upper respiratory tract infection	13.6% 72/528 • Number of events 131 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	17.1% 91/531 • Number of events 151 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.9% 6/206 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	16.2% 12/74 • Number of events 13 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	11.8% 9/76 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Urinary tract infection	5.5% 29/528 • Number of events 50 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	5.5% 29/531 • Number of events 33 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.4% 9/206 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.2% 2/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Viral rhinitis	1.3% 7/528 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.75% 4/531 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Viral upper respiratory tract infection	4.5% 24/528 • Number of events 31 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.2% 17/531 • Number of events 23 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.7% 2/74 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.9% 3/76 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.2% 2/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Vulval abscess	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Contusion	2.7% 14/528 • Number of events 20 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.7% 9/531 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Facial bones fracture	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Fall	1.7% 9/528 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.3% 12/531 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.9% 4/206 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	5.3% 4/76 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.2% 2/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Joint dislocation	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Injury, poisoning and procedural complications Ligament sprain	2.3% 12/528 • Number of events 14 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.7% 9/531 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Glucose tolerance impaired	0.57% 3/528 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Metabolism and nutrition disorders Hypokalaemia	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Arthralgia	5.1% 27/528 • Number of events 46 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.0% 21/531 • Number of events 23 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 3/206 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.7% 2/74 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.9% 3/76 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Myalgia	2.3% 12/528 • Number of events 15 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.1% 11/531 • Number of events 13 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.8% 5/74 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Pain in extremity	3.4% 18/528 • Number of events 21 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.1% 11/531 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.7% 2/74 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.95% 5/528 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.56% 3/531 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Anosmia	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Cerebral arteriosclerosis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Cerebrovascular disorder	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Nervous system disorders Headache	11.0% 58/528 • Number of events 157 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	10.2% 54/531 • Number of events 101 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.3% 13/206 • Number of events 18 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	12.2% 9/74 • Number of events 16 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	13.2% 10/76 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Asthma	2.7% 14/528 • Number of events 17 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.7% 25/531 • Number of events 27 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	8.1% 6/74 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	11.8% 9/76 • Number of events 16 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Nasal polyps	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.75% 4/531 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.6% 5/76 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	5.7% 30/528 • Number of events 39 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 22/531 • Number of events 31 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 3/206 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Respiratory, thoracic and mediastinal disorders Sleep apnoea syndrome	0.95% 5/528 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.1% 6/531 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Acne	0.76% 4/528 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Dry skin	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Photodermatosis	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Pruritus	0.76% 4/528 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.7% 9/531 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Rash	1.3% 7/528 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 7/531 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.2% 2/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Skin and subcutaneous tissue disorders Rash macular	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.19% 1/531 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Vascular disorders Hypertension	5.7% 30/528 • Number of events 39 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.9% 26/531 • Number of events 40 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.9% 4/206 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.8% 5/74 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	9.2% 7/76 • Number of events 7 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	12.5% 4/32 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Eye disorders Cataract	1.3% 7/528 • Number of events 8 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.7% 2/74 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.9% 3/76 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Eye disorders Retinal tear	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Dental caries	0.57% 3/528 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.1% 6/531 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Dyspepsia	1.3% 7/528 • Number of events 13 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.75% 4/531 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Gastrointestinal disorders Nausea	3.0% 16/528 • Number of events 19 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.7% 9/531 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.2% 2/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Impaired healing	0.00% 0/528 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/531 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Influenza like illness	4.9% 26/528 • Number of events 28 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.7% 25/531 • Number of events 29 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	7.9% 6/76 • Number of events 6 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
General disorders Pyrexia	2.3% 12/528 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.7% 9/531 • Number of events 11 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Immune system disorders Hypersensitivity	0.19% 1/528 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.38% 2/531 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/206 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/76 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Bronchitis	5.5% 29/528 • Number of events 44 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	7.3% 39/531 • Number of events 51 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	12.2% 9/74 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.9% 3/76 • Number of events 3 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Covid-19	1.3% 7/528 • Number of events 8 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 8/531 • Number of events 8 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.9% 10/206 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	6.8% 5/74 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	12.5% 4/32 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Chronic sinusitis	1.7% 9/528 • Number of events 13 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.1% 6/531 • Number of events 8 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	4.1% 3/74 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	5.3% 4/76 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Cystitis	1.5% 8/528 • Number of events 9 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.7% 9/531 • Number of events 11 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.49% 1/206 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Gastroenteritis	4.7% 25/528 • Number of events 26 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.0% 16/531 • Number of events 17 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.4% 5/206 • Number of events 5 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	2.7% 2/74 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/32 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Lower respiratory tract infection bacterial	1.7% 9/528 • Number of events 11 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 8/531 • Number of events 10 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.5% 3/206 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.4% 1/74 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Nasopharyngitis	24.6% 130/528 • Number of events 220 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	23.4% 124/531 • Number of events 222 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	10.2% 21/206 • Number of events 26 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	24.3% 18/74 • Number of events 27 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	28.9% 22/76 • Number of events 38 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	21.9% 7/32 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.
Infections and infestations Otitis media	1.9% 10/528 • Number of events 12 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.75% 4/531 • Number of events 4 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.97% 2/206 • Number of events 2 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	0.00% 0/74 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	1.3% 1/76 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.	3.1% 1/32 • Number of events 1 • Baseline (Week 0 in predecessor study) to long-term extension completion (either weeks 104 or 116). Includes AEs with onset date between the date of first dose of IP and and the long-term extension completion or withdrawal date (on-study period) The subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION are included in both Rand Pbo and Pbo to Teze arms. Their data collected during the placebo (predecessor) period are contained within the Rand Pbo arm, while data collected after the first dose of tezepelumab in DESTINATION are presented in the Pbo to Teze arm. Note the primary objective in the Outcome Measures section presents on-treatment safety as opposed to on-study safety.

Additional Information

Global Clinical Head

AstraZeneca

Phone: +1 302 885 1180

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place